AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...
On Friday, when AbbVie reported its quarterly earnings, the pharma giant jacked up its 2027 projected sales of Humira follow-ons Skyrizi and Rinvoq to a combined $31 billion. It is a $4 billion ...
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback